Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug
California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.
California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.